No Data
Zhejiang East-Asia Pharmaceutical (605177.SH) granted 2.1701 million shares of restricted stocks at a grant price of 9.47 yuan per share.
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that the fourth director's meeting will be held on December 6, 2024...
Zhejiang East Asia Pharmaceutical Gets South Korea Nod for Dyspepsia Drug
Zhejiang East-Asia Pharmaceutical (605177.SH): The active pharmaceutical ingredient Mosapride Citrate has obtained the original pharmaceutical registration certificate in South Korea.
Gelonghui December 4th | Zhejiang East-Asia Pharmaceutical (605177.SH) announced that it has received the active pharmaceutical ingredient registration certificate from the South Korea Food and Drug Administration (MFDS) for the product named Mosapride Citrate. Mosapride Citrate is used for functional dyspepsia accompanied by gastric heartburn, belching, nausea, vomiting, early satiety, epigastric bloating, and other digestive symptoms; it can also be used for gastroesophageal reflux disease, diabetic gastroparesis, and gastric functional disorders in some patients with partial gastrectomy.
Zhejiang East Asia Pharmaceutical Subsidiary Gets European CEP Certificate for Antibacterial Drug API Method
Zhejiang East-Asia Pharmaceutical (605177.SH): The active pharmaceutical ingredient of cefaclor (enzyme method) has obtained the CEP certificate in Europe.
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that its wholly-owned subsidiary Zhejiang Dongbang Pharmaceutical Co., Ltd. has received a notification from Europe...
Earnings Troubles May Signal Larger Issues for Zhejiang East Asia Pharmaceutical (SHSE:605177) Shareholders
Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Might Not Be As Mispriced As It Looks After Plunging 31%
